Shanghai Forefront Pharma Co.Ltd.
| Shanghai Forefront Pharma is a R&D driven and innovation focused novel biopharmaceutical company. The company focuses on high-end generics as well as innovative drugs. For the high-end generics, ForeFront's portfolio includes difficult-to-synthesis molecules which may also involve semisynthetic, innovative drug delivery systems such as CR & SR formulation, fixed dose combination technologies, etc.. The company targets to file P IV and 505b2 in US and EU, and aims to file Category 2, 3, 4, and 5 drugs in China independently and/or in collaboration with strategic partners. The company is active in Antiviral, CVS, and orphan disease areas for both generic and innovative drugs. Forefront has sophisticated equipment to support its ambitions in synthesis, analytical, and formulation activities. ForeFront's vision is to become a leading generic company in R&D in China and to own a competitive portfolio in generics. Over mid and long term, ForeFront will steadily grow its new drug business to develop into a full scale pharmaceutical company with competitive portfolio, sufficient capital support, strong R&D and innovation capabilities to develop generic and new drugs to satisfy patient needs worldwide. |
